A Study of NX-019 in Patients with Advanced, Epidermal Growth Factor Receptor (EGFR) Mutant Cancer

Clinical trial NCT05514496 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05514496
Sponsor: Nalo Therapeutics Inc.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

EGFR Mutation-Related Tumors

Start date: 2022-10-05
Primary completion: 2025-06-01
Enrollment: 258

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.